Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan
Ironwood Pharmaceuticals | January 29, 2017
Astellas Pharma Inc. (TSE:4503) and Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today top-line results indicating that the Phase III clinical trial of linaclotide conducted in Japan in adults with chronic constipation (CC) met its primary endpoint.